J. Nguyen

发表

Views on amyloid hypothesis and secretase inhibitors for treating Alzheimer's disease: progress and problems.

Y. Kiso, J. Nguyen, A. Yamani, 2006, Current pharmaceutical design.

Oligoarginine-based prodrugs with self-cleavable spacers for caco-2 cell permeation.

S. Futaki, T. Fujita, Y. Kiso, 2008, Chemical & pharmaceutical bulletin.

Development of oligoarginine-drug conjugates linked to new peptidic self-cleavable spacers toward effective intestinal absorption.

S. Futaki, T. Fujita, Y. Kiso, 2007, Bioorganic & medicinal chemistry letters.

beta-Secretase inhibitors: modification at the P4 position and improvement of inhibitory activity in cultured cells.

Kazuki Saito, Y. Kiso, Y. Hamada, 2006, Bioorganic & medicinal chemistry letters.

BACE1 inhibitors: optimization by replacing the P1' residue with non-acidic moiety.

Kazuki Saito, Y. Kiso, Y. Hamada, 2008, Bioorganic & medicinal chemistry letters.

Design of Potent Aspartic Protease Inhibitors to Treat Various Diseases

Y. Kiso, Y. Hamada, Tooru Kimura, 2008, Archiv der Pharmazie.

Human T-cell Leukemia Virus Type I (HTLV-I) Retropepsin

Y. Kiso, J. Nguyen, 2013 .

Oxidation of Electron Donor-Substituted Verdazyls: Building Blocks for Molecular Switches.

J. Nguyen, R. Cheng, D. J. Brook, 2015, The journal of physical chemistry. A.

Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles.

Y. Kiso, Tooru Kimura, J. Nguyen, 2011, Bioorganic & medicinal chemistry letters.

Rational Drug Design of HTLV-I Protease Inhibitors

Y. Kiso, J. Nguyen, 2009 .

Discovery of Peptide Drugs as Enzyme Inhibitors and Activators

Y. Kiso, J. Nguyen, 2015 .

Effects of calcium channel antagonists on the release of prostaglandin E2 from metabolically stressed muscle.

M. Brooke, J. Nguyen, R. Majumdar, 1994, Biochemical pharmacology.

Development of [Ile40]HTLV‐I protease inhibition assay using novel fluorogenic and chromogenic substrate

Y. Kiso, Tooru Kimura, Y. Hayashi, 2011, Journal of peptide science : an official publication of the European Peptide Society.

Delivery of Peptide Drugs

Y. Kiso, J. Nguyen, 2015 .

Hantzsch 1,4-dihydropyridines containing a diazen-1-ium-1,2-diolate nitric oxide donor moiety to study calcium channel antagonist structure-activity relationships and nitric oxide release.

J. Nguyen, E. Knaus, Carlos A. Velázquez, 2005, Bioorganic & medicinal chemistry.

Structure-guided design and synthesis of P1' position 1-phenylcycloalkylamine-derived pentapeptidic BACE1 inhibitors.

Y. Kiso, Y. Hamada, Tooru Kimura, 2011, Bioorganic & medicinal chemistry.

Hantzsch 1,4‐dihydropyridines containing a nitrooxyalkyl ester moiety to study calcium channel antagonist structure–activity relationships and nitric oxide release

J. Nguyen, E. Knaus, C. McEwen, 2000 .

Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.

Y. Kiso, Y. Hamada, Tooru Kimura, 2008, Journal of medicinal chemistry.

Design of pentapeptidic BACE1 inhibitors with carboxylic acid bioisosteres at P1' and P4 positions.

Y. Kiso, Y. Hamada, Tooru Kimura, 2010, Bioorganic & medicinal chemistry.

Design and synthesis of potent beta-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres.

Kazuki Saito, Y. Kiso, Y. Hamada, 2006, Bioorganic & medicinal chemistry letters.

Chipping at large, potent human T-cell leukemia virus type 1 protease inhibitors to uncover smaller, equipotent inhibitors.

K. Nishiyama, Y. Kiso, Tooru Kimura, 2007, Bioorganic & medicinal chemistry letters.

Maintaining potent HTLV-I protease inhibition without the P3-cap moiety in small tetrapeptidic inhibitors.

Y. Kiso, Tooru Kimura, J. Nguyen, 2011, Bioorganic & medicinal chemistry letters.

Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme.

Y. Kiso, Tooru Kimura, Y. Hayashi, 2008, Bioorganic & medicinal chemistry.

Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.

Y. Kiso, Tooru Kimura, Y. Hayashi, 2008, Bioorganic & medicinal chemistry.

Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors.

K. Nishiyama, Y. Kiso, Tooru Kimura, 2008, Bioorganic & medicinal chemistry letters.

Available online

A. Wlodawer, A. Gustchina, Mi Li, 2010 .

Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.

A. Molla, D. Kempf, R. Kuroki, 2009, Journal of medicinal chemistry.

Syntheses, calcium channel agonist‐antagonist modulation effects, and nitric oxide release studies of [3‐(Benzenesulfonyl)furoxan‐4‐yloxy]alkyl 1,4‐Dihydro‐2,6‐dimethyl‐5‐nitro‐4‐(2‐trifluoromethylphenyl, benzofurazan‐4‐yl, 2‐, 3‐, or 4‐pyridyl)‐3‐pyridinecarboxylates

J. Nguyen, E. Knaus, D. Vo, 2002 .

Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.

D. Kempf, R. Kuroki, Y. Kiso, 2018, Journal of medicinal chemistry.

Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.

Y. Kiso, Y. Hamada, Tooru Kimura, 2007, Bioorganic & medicinal chemistry letters.

Novel BACE1 inhibitors with a non-acidic heterocycle at the P1' position.

Y. Kiso, Y. Hamada, J. Nguyen, 2013, Bioorganic & Medicinal Chemistry.

Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme.

Y. Kiso, Tooru Kimura, Y. Hayashi, 2008, Bioorganic & medicinal chemistry.